Developing Novel Solutions
for Brain and
Inflammatory Disorders
Mission Statement

To develop novel solutions for brain and inflammatory disorders


To be a world class innovation driven biopharmaceutical company to improve the quality of life of patients


Commitment, hard work and integrity

FSD Pharma is bringing innovative neuro and inflammatory disorders therapies to millions of patients in need.
FSD Pharma has the following 3 drug candidates in its pipeline:
A patented, proprietary neuroprotective new chemical entity (NCE) that has demonstrated in preclinical models the potential to reverse and prevent myelin degradation, an underlying cause of Multiple Sclerosis and other neurodegenerative orders
Know more
A unique psychedelic molecule currently undergoing IND enabling studies with a targeted treatment for neuropsychiatric disorders, such as Major Depressive Disorder.
Know more
An ultra micro PEA compound for inflammatory conditions. Phase 1 FDA approved trials returned positive topline results. Phase-2 trial for nociplastic pain associated with Idiopathic Mast Cell Activation Syndrome (Disorder) are currently ongoing
Know more
Armed with a strong balance sheet, solid pipeline, and renowned clinical team, FSD intends to advance its lead drug candidates through clinical trials with the goal of providing therapies to the millions suffering from neurodegenerative and neuropsychiatric conditions.
Today there is no cure for Multiple Sclerosis (MS). FSD Pharma will attempt to change that for millions of suffering people. FSD’s proprietary compound Lucid-MS has shown promising results to reverse progressive MS, in several animal models
Well positioned to advance current pipeline and aggressively pursue additional acquisitions that present compelling opportunities across the psychedelics and innovative biotech space focused on “Total Brain Health”
Renowned clinical team led by Dr. Lakshmi P. Kotra, who is the recipient of the Julia Levy Award, is a Senior Scientist at Krembil Brain Institute, as well as University Health Network (UHN), and Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra serves as CEO of FSD Pharma’s wholly owned subsidiary, Lucid Psycheceuticals
Competitive Advantage / VALUE PROPOSITION

World-Class Pipeline

Neurodegenerative and neuropsychiatric disease, multi-billion dollar markets, unmet need, decades of research de-risk our drugs
Lucid-MS: New Chemical Entity for Multiple Sclerosis, pre-clinical research re-established use of paralyzed rear legs in MS mouse model, research published in peer-reviewed journals. On 17th of January 2023 FSD Pharma has submitted its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first in-human safety and tolerability investigation
FSD201: Proprietary ultra-micro PEA (palmitoylethanolamide) compound, solid safety profile in humans, Phase-2 clinical trials for inflammatory disease is currently ongoing
Lucid-Psych: Novel pathway (unique MOA) to treat Major Depressive Disorder, Phase 1 clinical trial targeted for end of first quarter of 2023
IP Estate: FSD Pharma has rights to patent families licensed on an exclusive basis

Elite Team

FSD Pharma’s flagship subsidiary led by Dr. Lakshmi Kotra, the recipient of the Julia Levy Award and a senior scientist at the Krembil Brain Institute, as well as the world-renowned University Health Network (UHN).
FSD Pharma has a world class team working full-time on pipeline development, with backgrounds at the FDA, major pharmaceuticals firms, and esteemed universities.
FSD Pharma team includes 2 Julia Levy Award recipients, a distinguished award that has only been awarded to 8 recipients since its inception in 2005 (no other company can make this claim)

Strong Cash Position

Cash enough to carry operations (including 3 planned clinical trials)
No dilution on horizon for shareholders

Solid Cap Table / Insider Ownership

Only 38.1 million shares issued
Share repurchase plan ongoing, approximately 2 million shares returned to treasury in 2022
Co-founders, directors and other insiders frequently buying shares since start of 2022 and continue to accumulate shares. This can be verified by checking the SEDI filings

*Data current as of October 03, 2022
A strong balance sheet represented by no debt and enough of working capital including taking the 3 different molecules through clinical trials
Developing novel myelin repairing compounds for the treatment of neurodegenerative and neuropsychiatric diseases
Two lead candidatesvto improve patient outcomes and address large populations ($23B multiple sclerosis market and $238B mental health market)
Lead compound, FSD201, a proprietary ultra micro PEA compound, has shown effective anti-inflammatory properties and a favorable safety profile proving potential viability for a range of conditions
Well capitalized to pursue acquisitions that advance our mission to deliver today’s most innovative treatments for Total Brain Health
On 17th of January FSD Pharma has submitted its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first in-human safety and tolerability investigation. This trial will be First In Class for its Multiple Sclerosis drug candidate
Begin the process of advancing clinical trials for the treatment of depression, anxiety and psychiatric disorders through its psychedelic molecule Lucid-Psych by the end of first quarter of 2023
Advancement of FSD-201 for phase-2 trials for chronic widespread musculoskeletal nociplastic pain associated with Idiopathic Mast Cell Activation Syndrome (Disorder) which is currently ongoing.
World class and experienced team of scientists, researchers and doctors from world class institutions or organizations
Goals, strategies
focus on developing
the assets in three therapeutic areas, and acquire assets to augment the efforts to complete phase 2 clinical trials, and enter phase 3 clinical trials.
look for opportunities
to strategically integrate artificial intelligence and computer modeling and sustainability for innovative therapeutic solutions, while pursuing its mission.
continually evaluate
its direction and explore opportunities to strengthen its mission and the pipeline
Board Diversity Matrix (as of August 8, 2022)

Receive most valuable updates straight into your inbox






    Email Alerts

    Please fill out the form below to receive company press releases via email when they occur.